Lever­ag­ing Can­cer Biol­o­gy for Ther­a­peu­tic Inno­va­tion: Clin­i­cal and Dis­cov­ery Advances at Ryvu

Ryvu Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny advanc­ing a broad and dif­fer­en­ti­at­ed oncol­o­gy port­fo­lio designed to address high-unmet med­ical needs by tar­get­ing key mech­a­nisms in can­cer biol­o­gy, from dys­reg­u­lat­ed kinas­es to syn­thet­ic lethal­i­ty and pre­ci­sion med­i­cine plat­forms. Our pipeline com­pris­es both inno­v­a­tive clin­i­cal can­di­dates and dis­cov­ery pro­grams that exem­pli­fy nov­el approach­es to treat­ing chal­leng­ing malignancies.

At the fore­front of our clin­i­cal efforts is romaci­clib (RVU120), a first-in-class, oral­ly bioavail­able selec­tive CDK8/CDK19 inhibitor that mod­u­lates tran­scrip­tion­al pro­grams dri­ving can­cer cell sur­vival. Romaci­clib is being eval­u­at­ed across mul­ti­ple Phase II stud­ies, with focus on relapsed or refrac­to­ry acute myeloid leukemia (AML) and myelofi­bro­sis, where encour­ag­ing sig­nals of activ­i­ty and a good safe­ty pro­file have been observed. Oth­er clin­i­cal stud­ies are inves­ti­gat­ing romaci­clib in low­er-risk myelodys­plas­tic syn­dromes and pedi­atric medulloblastoma.

In par­al­lel, dapolsert­ib (MEN1703/SEL24), a dual PIM/FLT3 kinase inhibitor licensed to the Menar­i­ni Group, is pro­gress­ing in Phase II devel­op­ment in dif­fuse large B‑cell lym­phoma (DLB­CL).

Beyond these clin­i­cal assets, Ryvu’s ONCO Prime dis­cov­ery plat­form sup­ports the dis­cov­ery of nov­el pre­ci­sion tar­gets in CRC, TNBC and lung can­cers. Sep­a­rate­ly, Ryvu is advanc­ing ADC pro­grams that incor­po­rate inno­v­a­tive pay­loads, there­by broad­en­ing the range of poten­tial future therapies.

Togeth­er, these pro­grams reflect Ryvu’s com­mit­ment to advanc­ing pre­ci­sion oncol­o­gy by inte­grat­ing deep bio­log­i­cal insights with trans­la­tion­al sci­ence, fos­ter­ing col­lab­o­ra­tions that accel­er­ate the deliv­ery of impact­ful ther­a­pies for patients.

Ryvu Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny advanc­ing a broad and dif­fer­en­ti­at­ed oncol­o­gy port­fo­lio designed to address high-unmet med­ical needs by tar­get­ing key mech­a­nisms in can­cer biol­o­gy, from dys­reg­u­lat­ed kinas­es to syn­thet­ic lethal­i­ty and pre­ci­sion med­i­cine plat­forms. Our pipeline com­pris­es both inno­v­a­tive clin­i­cal can­di­dates and dis­cov­ery pro­grams that exem­pli­fy nov­el approach­es to treat­ing chal­leng­ing malignancies.

At the fore­front of our clin­i­cal efforts is romaci­clib (RVU120), a first-in-class, oral­ly bioavail­able selec­tive CDK8/CDK19 inhibitor that mod­u­lates tran­scrip­tion­al pro­grams dri­ving can­cer cell sur­vival. Romaci­clib is being eval­u­at­ed across mul­ti­ple Phase II stud­ies, with focus on relapsed or refrac­to­ry acute myeloid leukemia (AML) and myelofi­bro­sis, where encour­ag­ing sig­nals of activ­i­ty and a good safe­ty pro­file have been observed. Oth­er clin­i­cal stud­ies are inves­ti­gat­ing romaci­clib in low­er-risk myelodys­plas­tic syn­dromes and pedi­atric medulloblastoma.

In par­al­lel, dapolsert­ib (MEN1703/SEL24), a dual PIM/FLT3 kinase inhibitor licensed to the Menar­i­ni Group, is pro­gress­ing in Phase II devel­op­ment in dif­fuse large B‑cell lym­phoma (DLB­CL).

Beyond these clin­i­cal assets, Ryvu’s ONCO Prime dis­cov­ery plat­form sup­ports the dis­cov­ery of nov­el pre­ci­sion tar­gets in CRC, TNBC and lung can­cers. Sep­a­rate­ly, Ryvu is advanc­ing ADC pro­grams that incor­po­rate inno­v­a­tive pay­loads, there­by broad­en­ing the range of poten­tial future therapies.

Togeth­er, these pro­grams reflect Ryvu’s com­mit­ment to advanc­ing pre­ci­sion oncol­o­gy by inte­grat­ing deep bio­log­i­cal insights with trans­la­tion­al sci­ence, fos­ter­ing col­lab­o­ra­tions that accel­er­ate the deliv­ery of impact­ful ther­a­pies for patients.

Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu
Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu
Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu

Mile­na Mazan

Dr Mile­na Mazan is a Head of Trans­la­tion­al Med­i­cine at Ryvu Ther­a­peu­tics, with a PhD in Can­cer Research and over 10 years of expe­ri­ence in oncol­o­gy, trans­la­tion­al research, bio­mark­er strat­e­gy, and clin­i­cal devel­op­ment. Her work focus­es on bridg­ing explorato­ry research and clin­i­cal appli­ca­tion through bio­mark­er-dri­ven stud­ies sup­port­ing the devel­op­ment of nov­el can­cer therapies.

At Ryvu, Dr Mazan is respon­si­ble for the devel­op­ment and exe­cu­tion of the trans­la­tion­al research plan for most advanced com­pounds, coör­di­nat­ing pre­clin­i­cal research activ­i­ties, exter­nal sci­en­tif­ic col­lab­o­ra­tions, and bio­mark­er analy­ses sup­port­ing clin­i­cal devel­op­ment. Her cur­rent work con­tributes to the advance­ment of treat­ment strate­gies in acute myeloid leukemia and sol­id tumors.

Dr Mazan com­plet­ed her MSc stud­ies at Jagiel­lon­ian Uni­ver­si­ty and the Uni­ver­si­ty of Orléans, and obtained her PhD at the Man­ches­ter Can­cer Research Cen­tre, where she stud­ied tran­scrip­tion­al mech­a­nisms involved in hematopoiesis and malig­nant trans­for­ma­tion. She lat­er worked at the Well­come Trust Sanger Insti­tute in Cam­bridge, focus­ing on leukemia biol­o­gy and ther­a­peu­tic tar­get identification.

Since join­ing Ryvu in 2016, she has held senior sci­en­tif­ic and lead­er­ship roles and con­tributed to oncol­o­gy pro­grams includ­ing romaci­clib and dapolsertib.

Learn more about Ryvu.

Dr Mile­na Mazan is a Head of Trans­la­tion­al Med­i­cine at Ryvu Ther­a­peu­tics, with a PhD in Can­cer Research and over 10 years of expe­ri­ence in oncol­o­gy, trans­la­tion­al research, bio­mark­er strat­e­gy, and clin­i­cal devel­op­ment. Her work focus­es on bridg­ing explorato­ry research and clin­i­cal appli­ca­tion through bio­mark­er-dri­ven stud­ies sup­port­ing the devel­op­ment of nov­el can­cer therapies.

At Ryvu, Dr Mazan is respon­si­ble for the devel­op­ment and exe­cu­tion of the trans­la­tion­al research plan for most advanced com­pounds, coör­di­nat­ing pre­clin­i­cal research activ­i­ties, exter­nal sci­en­tif­ic col­lab­o­ra­tions, and bio­mark­er analy­ses sup­port­ing clin­i­cal devel­op­ment. Her cur­rent work con­tributes to the advance­ment of treat­ment strate­gies in acute myeloid leukemia and sol­id tumors.

Dr Mazan com­plet­ed her MSc stud­ies at Jagiel­lon­ian Uni­ver­si­ty and the Uni­ver­si­ty of Orléans, and obtained her PhD at the Man­ches­ter Can­cer Research Cen­tre, where she stud­ied tran­scrip­tion­al mech­a­nisms involved in hematopoiesis and malig­nant trans­for­ma­tion. She lat­er worked at the Well­come Trust Sanger Insti­tute in Cam­bridge, focus­ing on leukemia biol­o­gy and ther­a­peu­tic tar­get identification.

Since join­ing Ryvu in 2016, she has held senior sci­en­tif­ic and lead­er­ship roles and con­tributed to oncol­o­gy pro­grams includ­ing romaci­clib and dapolsertib.

Learn more about Ryvu.

Milena Mazan
Mile­na Mazan, Ryvu Ther­a­peu­tics, POLAND

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session